Ajinomoto and Olon Join Forces for Innovative Peptide and Protein Manufacturing Ajinomoto Bio-Pharma Services partners with Olon S.p.A. to enhance large-scale peptide and protein manufacturing, focusing on sustainability and efficiency.

Ajinomoto and Olon Join Forces for Innovative Peptide and Protein Manufacturing #USA #Ajinomoto #Peptide_Manufacturing #Olon #Tokyo_and_Milan

Ajinomoto Bio-Pharma and Olon Unite to Revolutionize Peptide Manufacturing Ajinomoto Bio-Pharma Services and Olon S.p.A. have formed a strategic alliance to enhance peptide and protein manufacturing, focusing on sustainability and innovation.

Ajinomoto Bio-Pharma and Olon Unite to Revolutionize Peptide Manufacturing #Japan #Tokyo #Peptide_Manufacturing #Ajinomoto_Bio-Pharma #Olon_S.p.A.

Cambrex Expands Peptide Manufacturing Capabilities in Waltham, Massachusetts Cambrex Corporation has recently enhanced its peptide manufacturing facility in Waltham, Massachusetts, expanding capabilities and supporting innovative therapy development.

Cambrex Expands Peptide Manufacturing Capabilities in Waltham, Massachusetts #Waltham #Cambrex #Peptide_Manufacturing #Snapdragon_Chemistry

CordenPharma Unveils Major Construction Plans for Peptide Manufacturing Facility in Switzerland CordenPharma is set to invest over €1 billion in expanding its peptide manufacturing capabilities, including a new facility in Switzerland, aiming for heightened production by 2028.

CordenPharma Unveils Major Construction Plans for Peptide Manufacturing Facility in Switzerland #Switzerland #Basel #CordenPharma #Peptide_Manufacturing

CordenPharma Boosts Peptide Manufacturing with Major Greenfield Investment in Switzerland CordenPharma is set to invest over €1 billion in peptide manufacturing growth, focusing on a new greenfield facility near Basel, Switzerland.

CordenPharma Boosts Peptide Manufacturing with Major Greenfield Investment in Switzerland #Switzerland #Basel #CordenPharma #Peptide_Manufacturing #Muttenz

CordenPharma Unveils Over €500 Million Investment in New Peptide Facility in Switzerland CordenPharma is investing over €500 million to establish a state-of-the-art peptide facility in Basel, Switzerland, enhancing its production capabilities.

CordenPharma Unveils Over €500 Million Investment in New Peptide Facility in Switzerland #Switzerland #Basel #CordenPharma #Peptide_Manufacturing #Basel_Switzerland